> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.4% Of Verastem In A Passive Position Measured In September
- URL: https://www.bullished.co/state-street-holds-4-4-of-verastem-in-a-passive-position-measured-in-september-64a0738f/
- Published: 2026-11-10T14:40:58.000Z
- Updated: 2026-11-10T14:40:58.000Z
- Description: Verastem expects October financing and cancer-drug revenue to support operations into the first half of 2028.
- Author: Matteo Parrino
- Tags: SEC Filings, VSTM, Industry: Healthcare

State Street reported a [4.4% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000741/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Verastem](https://www.bullished.co/tag/vstm/), which develops and sells cancer medicines, in an SEC ownership disclosure filed Tuesday. The position comprised 4,020,999 common shares as of September 30, rather than a purchase established on the filing date.

## A Passive Position, Not A Control Bid

State Street certified that the holding arose from its ordinary business activities and was not intended to change or influence Verastem's control.

The company reported [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000741/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 3,933,505 shares, with no sole voting power. It also reported shared power to dispose of 4,020,999 shares.

## October Funding Supports The Cancer Pipeline

Verastem raised capital after mixed third-quarter results. Management expects the October financing, together with CO-PACK revenue, to [fund operations into](https://seekingalpha.com/news/4668488-verastem-expects-october-financing-and-co-pack-revenue-to-fund-operations-into-first-half-of?ref=bullished.co) the first half of 2028.

Its commercial product, AVMAPKI FAKZYNJA CO-PACK, pairs avutometinib capsules with defactinib tablets. Approved in the United States, it treats adults whose KRAS-mutated recurrent low-grade serous ovarian cancer has previously received systemic therapy. Specialty pharmacies and distributors sell the treatment; its first full seven months on the market generated $30.9 million in net product revenue in 2025.

Verastem's medicines target cancers driven by RAS/MAPK, a cell-signaling pathway involved in tumor growth. Its development pipeline includes VS-7375, an oral KRAS G12D inhibitor licensed from GenFleet Therapeutics, in an early-stage trial involving pancreatic, lung and colorectal cancers, as well as preclinical programs.

Two doses of VS-7375 tested on their own cleared testing without toxicities that limited dosing. The program moved into combination testing with cetuximab.

## Recent Gains Meet A Longer Decline

As of Tuesday's original report, Verastem shares had gained 39.17% over 90 days, while the five-year shareholder return was down 75.11%.

Verastem's market capitalization was $1.1 billion at 9:38 a.m. ET Tuesday. The September ownership position and management's funding outlook provide separate context for a company balancing commercial sales with continued drug development.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: VERASTEM INC (VSTM)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000741/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Verastem (VSTM) Wins FDA Priority Review, Is The Stock Cheap Or Priced For More?](https://uk.finance.yahoo.com/news/verastem-vstm-wins-fda-priority-211234663.html?ref=bullished.co) — Yahoo Finance
- [Verastem expects october financing and CO-PACK revenue to fund operations into first half of 2028 (NASDAQ:VSTM) | Seeking Alpha](https://seekingalpha.com/news/4668488-verastem-expects-october-financing-and-co-pack-revenue-to-fund-operations-into-first-half-of?ref=bullished.co) — seekingalpha.com
- [Verastem Inc. (NASDAQ:VSTM) : Articles :: Law360](https://www.law360.com/companies/verastem-inc?ref=bullished.co) — law360.com

### More on Verastem

- [Verastem Pegs Pro Forma Cash At $422.8 Million, With Runway Into First Half Of 2028](https://www.bullished.co/verastem-pegs-pro-forma-cash-at-422-8-million-with-runway-into-first-half-of-2028-0e88310c/)
- [Verastem Says FDA Agreed To Make Survival A Secondary Goal In Pancreatic Cancer Trial](https://www.bullished.co/verastem-says-fda-agreed-to-make-survival-a-secondary-goal-in-pancreatic-cancer-trial-0aaded1d/)
- [Verastem Prices $250 Million Share Sale At $8.00, Above Last Sale, To Fund KRAS Drug](https://www.bullished.co/verastem-prices-250-million-share-sale-at-8-00-above-last-sale-to-fund-kras-drug-e363447b/)

[All Verastem (VSTM) coverage →](https://www.bullished.co/tag/vstm/)